Normeg (Levetiracetam)

• Levetiracetam is used in the management of several seizure types within the epileptic disorder spectrum.
• Partial onset seizures: reduces the frequency of focal seizures and improves daily functioning.
• Myoclonic seizures: diminishes rapid, involuntary muscle jerks associated with juvenile myoclonic epilepsy.
• Generalized tonic‑clonic seizures: helps prevent loss of consciousness and convulsive episodes in generalized epilepsy.

• Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a regulator of neurotransmitter release. This interaction modulates synaptic transmission, stabilising neuronal firing and decreasing the likelihood of hyper‑excitable neuronal networks that generate seizures.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: persistent tiredness not relieved by rest.
• Headache: mild to moderate cranial pain.
• Irritability: increased emotional lability.
• Nausea: feeling of queasiness or upset stomach.
• Somnolence: tendency to fall asleep during the day.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Mood changes: depression, suicidal thoughts, or aggressive behavior.
• Blood disorders: unexplained bruising or bleeding.
• Liver enzyme elevation: abnormal liver function tests.
• Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Seizure worsening: paradoxical increase in seizure frequency.

• Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly.
• Renal function: adjust dose in patients with impaired clearance.
• Psychiatric history: monitor for mood alterations or suicidal ideation.
• Concomitant CNS depressants: avoid excessive sedation when combined.
• Pregnancy and lactation: evaluate risk‑benefit ratio; data are limited.
• Elderly patients: start at lower dose and titrate cautiously.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Levetiracetam has a relatively low potential for drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid)

• Live vaccines: may reduce vaccine efficacy; avoid concurrent administration.
• Strong enzyme inducers (e.g., carbamazepine, phenytoin): can lower levetiracetam plasma levels.

Moderate Interactions (Monitor Closely)

• Sedative agents (e.g., benzodiazepines, alcohol): may increase central nervous system depression.
• Antidepressants (e.g., SSRIs): monitor for heightened irritability or mood changes.
• Antihypertensives: observe for potential blood pressure alterations.
• Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously.